DYAZIDE
LOE ApproachingNDAORALCAPSULE
Approved
Dec 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 9h ago · AI intelligence enriched 6d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
DYAZIDE is an oral capsule small-molecule drug approved in 1965 by GSK as an NDA product. The specific indication and mechanism of action are not documented in available data, limiting characterization of its therapeutic role. Based on its vintage approval date and capsule formulation, it represents a legacy therapeutic asset.
LOE Approaching
Product is approaching loss of exclusivity with moderate competitive pressure (30), indicating a contracting commercial footprint and likely downsizing of brand support infrastructure.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on DYAZIDE offers limited career growth opportunity given its LOE-approaching status and zero linked job openings. Roles available are likely focused on managed decline, generic strategy, or transition support rather than expansion or innovation.
Brand Manager (generic transition)Field Sales
Worked on DYAZIDE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.